- Home
- PODC vs NRXP Comparison
PODC vs NRXP Comparison
Compare PODC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PODC | NRXP |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.1M | 151.1M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PODC | NRXP |
|---|---|---|
| Price | $1.70 | $2.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.67 | ★ $38.50 |
| AVG Volume (30 Days) | 71.2K | ★ 660.5K |
| Earning Date | 11-10-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | $12.43 | $357.94 |
| Revenue Next Year | $18.96 | $1,507.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.41 | $1.65 |
| 52 Week High | $5.20 | $5.06 |
Technical Indicators
Market Signals| Indicator | PODC | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 34.30 | 29.50 |
| Support Level | N/A | $1.68 |
| Resistance Level | $2.57 | $2.49 |
| Average True Range (ATR) | 0.26 | 0.16 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 34.13 | 30.61 |
Price Performance
Historical ComparisonAbout PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more. It generates all its revenue from United States. PodcastOne has built a distribution network reaching over a billion monthly impressions across all channels, including YouTube, Spotify, Apple Podcasts, and iHeartRadio.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.